Close
Blog & Resources Camargo Blog May 11th, 2008

505(b)(2) Orphan Drug Approval With Only a BE Study?

A reader recently inquired about Orphan drugs and asked me if I thought an Orphan drug developed under 505(b)(2) could be approved based on just a Phase 1 study – a pharmacokinetic or pharmacodynamic comparison to the RLD.

At first I thought I couldn’t think of an example. Generally, an Orphan drug fulfills an unmet need in 200,000 or fewer people in the U.S. and requires a clinical study for approval. In return, among other benefits, the drug is given 7 years exclusivity – except, and here is a potential answer to the subject question:

If the new drug is shown to be different from the approved orphan drug because the new drug is “clinically superior” (e.g., shows greater efficacy,safety or contribution to patient care).

Thus, for example, you might find that a revised formulation significantly reduced adverse events. An Orphan injectable formulation is changed to reduce the injection site reactions, for instance. In this case, it is likely that only a Phase 1 study would be needed. We would recommend a pre-IND meeting with FDA to assure that FDA would consider the change ‘clinically superior’. The FDA has indicated that it would decide these matters on a case-by-case basis ( 57 Fed Reg 62079 – see particularly comment 27).



Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
2505 Meridian Parkway
Suite 150
Durham NC, 27713
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights